

Supplemental Table 6. Univariate analysis for patients exceeding the Milan criteria but fulfilling

the Hangzhou criteria (N=1352)

		N	Tumor-free survival rate (%)				<i>P</i> *
			1-yr	3-yr	5-yr	10-yr	
Age (yrs)	≤40	149	75.8	60.2	59.2	42.2	0.053
	40-50	446	79.2	55.6	51.3	30.1	
	>50	757	84.0	70.3	59.0	41.8	
Gender	Male	1232	81.7	64.4	56.9	38.7	0.46
	Female	120	79.0	63.9	51.8	-	
HBsAg	Positive	1218	81.0	63.9	56.5	34.1	0.42
	Negative	134	86.2	69.2	55.5	52.9	
Cirrhosis	Positive	1186	81.3	64.5	56.9	36.3	0.64
	Negative	166	79.1	63.3	53.9	38.4	
Hepatectomy	Yes	216	83.2	58.2	49.6	-	0.39
	No	1136	81.2	65.3	57.6	39.5	
Adjuvant therapy	Yes	599	81.6	67.0	58.1	36.5	0.76
	No	753	81.4	62.5	55.2	37.9	
Differentiation	High	431	85.5	69.0	58.3	35.7	0.33

(Edmondson)	Moderate	820	79.4	63.1	57.7	51.9	
	Low or none	101	80.6	56.2	48.3	-	
Tumor staging	I-II	809	83.6	67.0	60.1	42.5	0.16
(TNM)	III	481	77.3	59.4	52.1	-	
	IV	62	82.8	73.2	47.6	-	
Tumor burden	5-8	977	84.0	67.9	60.3	36.8	0.003
(cm)	>8	375	75.8	56.8	48.4	37.9	
Number	≤3	970	80.5	63.8	54.9	35.7	0.26
	>3	382	83.9	65.9	60.2	-	
AFP (ng/mL)	≤100	781	86.5	72.0	64.3	51.3	<0.001
	100-400	280	76.6	58.6	50.7	41.7	
	>400	291	72.8	50.0	41.8	0	
					-		
MELD	≤10	632	84.5	66.5	60.6	46.1	0.16
	>10	720	78.0	62.5	53.3	33.2	
Donor origin	Living donor	41	85.6	77.8	67.6	-	0.21
	Cadaveric	1311	81.1	63.9	56.3	36.7	
Year of	<2005	181	66.7	46.3	37.5	33.9	0.003

transplant	2005-2010	849	81.5	62.1	53.5	-
	>2010	322	89.6	-	-	-

Note. * Log-rank test; HBsAg, hepatitis B surface antigen; AFP, α -fetoprotein; MELD, model for end-stage liver diseases.